Loading stock data…
Autolus Therapeutics plc (AUTL)
$1.65+0.04 (+2.48%)
After Hours$1.65+0.00 (+0.00%)· Last close Jun 29
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Autolus Therapeutics plc in the Healthcare sector is trading at $1.65 with a market capitalization of $431M. Wall Street consensus targets $8.71 (9 analysts), implying a +427.9% move over the next 12 months. The stock is currently 39% below its 52-week high of $2.70, remaining 7.8% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +427.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $26.22M↑ | $24.29M↑ | $21.19M↑ | $20.92M↑ | $8.98M |
| Gross Profit | $1.65M↑ | -$1.04M↑ | -$7.45M↓ | -$3.52M↑ | -$8.97M |
| Operating Income | -$59.51M↑ | -$72.47M↓ | -$71.62M↓ | -$61.22M↑ | -$65.24M |
| Net Income | -$71.60M↑ | -$90.33M↓ | -$79.12M↓ | -$47.92M↑ | -$70.16M |
Peer Comparison
JNJUNHPFE
Fundamentals
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consist...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$431.15M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-265.53%
Volume
Today's trading volume
942,572
Recent News
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading
European equities traded in the US as American depositary receipts were lower late Wednesday morning
Autolus Therapeutics (AUTL) Stock Sees Split Analyst Revisions After Early Aucatyzl Launch Signals
Autolus Therapeutics is back in focus as analysts adjust price targets around the early commercial rollout of Aucatyzl, with some highlighting a recent move to US$10 while others have trimmed estimates by about US$2. These shifts reflect a split view, where bullish commentary leans on early demand signals in the U.S. and UK, and more cautious takes point to concentration risk around a single product and the potential for slower than expected uptake. Read on to see what is driving these...
Why Autolus Therapeutics (AUTL) Looks Less Speculative as AUCATZYL Revenue Builds
Autolus Therapeutics plc (NASDAQ:AUTL) is one of the small-cap stocks with potential to rise 1000 percent. Unlike many biotech companies that are still waiting for their first approved product, Autolus already has a treatment on the market. Its drug AUCATZYL, also known as obe-cel, is approved for adults with a hard-to-treat form of blood cancer […]
European Equities Traded in the US as American Depositary Receipts Slightly Higher in Tuesday Trading
European equities traded in the US as American depositary receipts were marginally higher Tuesday mo
European Equities Traded in the US as American Depositary Receipts Increase in Friday Trading; Rise for Week
European equities traded in the US as American depositary receipts were trending higher late Friday